Patients Discontinuing Anti-Obesity Medications Regain Weight at a Quadrupled Rate Compared to Those on Conventional Diets

A recent study reveals that patients who discontinue popular GLP-1 drugs like semaglutide or tirzepatide may regain shed pounds far faster than those who stop traditional diet and exercise programs.

Published data in a leading health publication points out that while obese individuals frequently drop a large proportion of their body weight while undergoing treatment, the mass returns at an estimated rate of 0.8 kg per month upon discontinuation.

"Users buying these drugs should be informed of the potential of fast rebound weight gain when the therapy concludes," cautioned expert Dr. Susan Jebb.

This pace of regain implies a reversion to pre-treatment weight within about a year and a half.

Comparing Approaches

The research, which looked at 37 of studies involving over 9,000 of patients, compared the results of the injectable medications with other pills.

Researchers point out that people who lose weight through diet and exercise typically see a slower weight regain—around 100 grams monthly—once they finish.

Understanding the Quick Regain

Nutrition scientists suggest the mode of action of the drugs accounts for the accelerated regain.

These medications mimic a body's own chemical called GLP-1, which controls feelings of fullness.

"Sustained high doses of GLP-1 levels far above than normal may cause the system to produce less of its own natural hormone, and may also lessen responsiveness to its actions," said Dr. Adam Collins, a dietetics expert.

"Withdrawal of this medication results in hunger is uncontrolled, making overeating a significant risk."

A Chronic Disease?

Medical guidelines advise the injections for individuals with weight-linked medical conditions, accompanied by prescribed diet and exercise modifications.

A number of clinicians say that, considering the significant potential of weight regain, the therapy might need to be long-term.

This opinion is echoed by pharmaceutical companies, who state that the findings "highlight the chronic character of obesity," akin to managing conditions like high blood pressure.

Patient Testimonies

Individuals who have stopped the medication explain a intense return of hunger.

"I experienced a switch that goes on and you become starving," said an individual.

This difficulty is compounded if individuals have not developed lasting lifestyle or habit modifications during therapy.

Growing Adoption

Figures show that millions of adults in the UK have tried these injections in the last 12 months, with interest continuing to grow.

• Adoption is greater among women compared to males.
• The 40s and 50s demographic shows the greatest usage rates.
• Many obtain the medications through private healthcare rather than the NHS.

Finally, clinicians caution that while these medications are potent tools for shedding pounds, they are not a standalone solution and maintained weight loss relies on ongoing behavioural management.